News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Versartis, Inc. (VSAR) To Hold Conference Call To Discuss Six Month VRS-317 Phase 2a VERTICAL Clinical Trial Results


6/9/2014 9:01:09 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

MENLO PARK, Calif., June 9, 2014 (GLOBE NEWSWIRE) -- Versartis, Inc. (Nasdaq:VSAR), an endocrine-focused biopharmaceutical company that is developing a novel, long-acting form of recombinant human growth hormone (rhGH) for the treatment of growth hormone deficiency (GHD), today announced it will hold a conference call and webcast on Monday, June 23, 2014 at 5:00 p.m. EDT (4:00 p.m. CDT).

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES